Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)

Inclusion Criteria: All women who received epidural, spinal, or combined spinal-epidural labour analgesia and presenting post-dural puncture headache: * Intense: with ≥3 / 10 numerical rating pain scale * Appearing within 5 days after delivery * Aggravating in sitting or standing position and / or improving supine * Can be associated with one of the following criteria: tinnitus, nausea, photophobia, neck stiffness or pain, hearing loss * After exclusion of clinically differential diagnoses (preeclampsia or eclampsia, cerebral venous thrombosis, migraine) * Age greater than or equal to 18 years * Affiliation to social security scheme * Inform Consent signed after oral and written information Exclusion Criteria: * Presence of diplopia (indication of immediate blood patch) * Contraindication to ACTH or Synacthène® (unbalanced hypertension, uncontrolled diabetes, uncontrolled psychosis, infectious viral disease state or evolving) * Processing of Torsade de Pointe provider (astenizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine) * Live vaccine in the months prior to inclusion * Hypersensitivity to Synacthène® * Patient who have previously received Synacthène® after delivery * Contraindication to blood patch (fever or leukocytosis, HIV or HCV patient) * Eclampsia or preeclampsia during this pregnancy * Patient who have received prophylactic blood patch (at diagnosis of Accidental Dural Puncture) * Minor under 18 or protected * Psychological disorders do not allowing informed consent * Refusal of participation in the study or participation in another ongoing interventional study * Withdrawal of consent